Q32 Bio Inc. — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Q32 Bio reported 36-week topline results from Part B of SIGNAL-AA trial of bempikibart (anti-IL-7Rα antibody) in 33 patients with severe/very severe alopecia areata: mean 35.3% reduction in SALT score (primary endpoint), 40% achieved SALT-20 response in mITT analysis, generally well-tolerated with no new safety signals. Company intends to advance into registration-directed program in first half of 2027.
Why this rating
Positive Phase 2a efficacy/safety data materially de-risks lead asset for $10.4M market-cap biotech; enables path to Phase 3/registration trial, pivotal for clinical-stage company survival and value.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.